Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate

Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis. The complete hematologic response in Indonesia is lower than in the wor...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ikhwan Rinaldi, Ary Harryanto Reksodiputro
Médium:	Artigo
Jazyk:	Indonésio
Vydáno:	Department of Internal Medicine, Faculty of Medicine Universitas Indonesia 2020-09-01
Edice:	Jurnal Penyakit Dalam Indonesia
Témata:	complete hematologic response imatinib mesylate
On-line přístup:	http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/461/245
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!